Patents by Inventor Leonard G. Presta

Leonard G. Presta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-CD39 antibodies and uses thereof
    Patent number: 10556959
    Abstract: The present disclosure relates generally to anti-CD39 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: February 11, 2020
    Assignee: Xencor, Inc.
    Inventors: Guoqing Chen, Gregory M. Hayes, Jan-Willem Theunissen, Edward Thein H. Van Der Horst, Leonard G. Presta
  • ANTI-C10ORF54 ANTIBODIES AND USES THEREOF
    Publication number: 20200040102
    Abstract: The present disclosure relates generally to anti-C10orf54 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.
    Type: Application
    Filed: July 23, 2019
    Publication date: February 6, 2020
    Applicant: Pierre Fabre Medicament
    Inventors: John LIPPINCOTT, Edward Thein Htun VAN DER HORST, Sun Young KIM, Leonard G. PRESTA
  • Anti-TREM2 antibodies and related methods
    Patent number: 10508148
    Abstract: Provided herein are anti-TREM2 antibodies and related methods of making and using anti-TREM2 antibodies. Also provided are methods and compositions for enhancing an immune response and/or for the treatment of an immune-related condition in an individual, e.g., cancer, comprising killing, disabling, or depleting non-stimulatory myeloid cells using an anti-TREM2 antibody or antigen binding fragment thereof.
    Type: Grant
    Filed: May 9, 2019
    Date of Patent: December 17, 2019
    Assignee: Pionyr Immunotherapeutics, Inc.
    Inventors: Michel Streuli, Venkataraman Sriram, Aritra Pal, Leonard G. Presta
  • Antigen-Binding Polypeptide Constructs Comprising Kappa and Lambda Light Chains and Uses Thereof
    Publication number: 20190338048
    Abstract: Provided herein are multispecific antigen-binding polypeptide constructs comprising at least two different heterodimers, each comprising a heavy chain and a light chain. At least one heterodimer comprises a Fab region comprising a lambda light chain and at least one heterodimer comprises a Fab region comprising a kappa light chain. One or more of the immunoglobulin heavy and light chains that form the antigen-binding polypeptide construct comprise amino acid modifications that promote correct pairing between the heavy and light chains to form the desired multispecific antigen-binding polypeptide construct. The amino acid modifications may be in the CH1 and/or CL domains, in the VH and/or VL domains, or a combination thereof.
    Type: Application
    Filed: October 7, 2016
    Publication date: November 7, 2019
    Inventors: Dunja UROSEV, Stacy A.L. TOM-YEW, Leonard G. PRESTA, Mario SANCHES
  • ANTI-IL1-RAP ANTIBODIES
    Publication number: 20190338038
    Abstract: Provided herein are antibodies specific for IL1-RAP.
    Type: Application
    Filed: October 16, 2017
    Publication date: November 7, 2019
    Applicant: Cellerant Therapeutics, Inc.
    Inventors: Ying Ping Jiang, Jagath R. Junutula, Leonard G. Presta
  • ANTI-TREM2 ANTIBODIES AND RELATED METHODS
    Publication number: 20190309064
    Abstract: Provided herein are anti-TREM2 antibodies and related methods of making and using anti-TREM2 antibodies. Also provided are methods and compositions for enhancing an immune response and/or for the treatment of an immune-related condition in an individual, e.g., cancer, comprising killing, disabling, or depleting non-stimulatory myeloid cells using an anti-TREM2 antibody or antigen binding fragment thereof.
    Type: Application
    Filed: May 9, 2019
    Publication date: October 10, 2019
    Inventors: Michel Streuli, Venkataraman Sriram, Aritra Pal, Leonard G. Presta
  • Anti-C10orf54 antibodies and uses thereof
    Patent number: 10421818
    Abstract: The present disclosure relates generally to anti-C10orf54 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: September 24, 2019
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: John Lippincott, Edward Thein Htun Van Der Horst, Sun Young Kim, Leonard G. Presta
  • Anti-C10orf54 antibodies and uses thereof
    Patent number: 10414823
    Abstract: The present disclosure relates generally to anti-C10orf54 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: September 17, 2019
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: John Lippincott, Edward Thein Htun Van Der Horst, Sun Young Kim, Leonard G. Presta
  • Anti-GITR antibodies
    Patent number: 10400040
    Abstract: Antibodies to human GITR are provided, as well as uses thereof, e.g., in treatment of proliferative and immune disorders.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: September 3, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Xiao Min Schebye, Grigori P. Ermakov, Douglas J. Hodges, Leonard G. Presta
  • ANTI-C10ORF54 ANTIBODIES AND USES THEREOF
    Publication number: 20190177415
    Abstract: The present disclosure relates generally to anti-C10orf54 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.
    Type: Application
    Filed: December 11, 2015
    Publication date: June 13, 2019
    Inventors: John LIPPINCOTT, Edward Thein Htun VAN DER HORST, Sung Young KIM, Leonard G PRESTA, Jan-Willem THEUNISSEN
  • IMMUNOGLOBULIN VARIANTS AND USES THEREOF
    Publication number: 20190071511
    Abstract: The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases.
    Type: Application
    Filed: February 26, 2018
    Publication date: March 7, 2019
    Applicant: Genentech, Inc.
    Inventors: Camellia W. ADAMS, Andrew C. CHAN, Craig W. CROWLEY, Henry B. LOWMAN, Gerald R. NAKAMURA, Leonard G. PRESTA
  • ANTI-C10ORF54 ANTIBODIES AND USES THEREOF
    Publication number: 20190031768
    Abstract: The present disclosure relates generally to anti-C10orf54 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.
    Type: Application
    Filed: August 2, 2018
    Publication date: January 31, 2019
    Inventors: John LIPPINCOTT, Edward Thein Htun VAN DER HORST, Sun Young KIM, Leonard G. PRESTA
  • ANTI-C10ORF54 ANTIBODIES AND USES THEREOF
    Publication number: 20190031767
    Abstract: The present disclosure relates generally to anti-C10orf54 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.
    Type: Application
    Filed: August 2, 2018
    Publication date: January 31, 2019
    Inventors: John LIPPINCOTT, Edward Thein Htun VAN DER HORST, Sun Young KIM, Leonard G. PRESTA
  • HUMANIZED ANTI-CLL-1 ANTIBODIES
    Publication number: 20180355044
    Abstract: Provided herein are humanized antibodies specific for CLL-1.
    Type: Application
    Filed: November 22, 2016
    Publication date: December 13, 2018
    Applicant: Cellerant Therapeutics, Inc.
    Inventors: Ying-Ping Jiang, Jagath R. Junutula, Leonard G. Presta, Naoya Tsurushita
  • Anti-C10orf54 antibodies and uses thereof
    Patent number: 10100123
    Abstract: The present disclosure relates generally to anti-C10orf54 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.
    Type: Grant
    Filed: June 6, 2014
    Date of Patent: October 16, 2018
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: John Lippincott, Edward Thein Htun Van Der Horst, Sun Young Kim, Leonard G. Presta
  • Antigen-Binding Constructs Targeting HER2
    Publication number: 20180273635
    Abstract: Described herein are high affinity antigen binding constructs, e.g., antibodies, directed to the ECD2 domain of HER2. The antigen-binding constructs comprise at least one antigen-binding polypeptide construct that binds to ECD2 of HER2 (HER2 ECD2) with increased affinity compared to a wild-type 2C4 antibody. Such antigen-binding polypeptide constructs comprise one or more amino acid modifications in the framework region and/or CDRs compared to the amino acid sequence of a wild-type 2C4 antibody that increase affinity of the antigen-binding polypeptide construct for ECD2 by 2-fold or greater. The antigen-binding constructs can inhibit the growth of HER2-expressing breast cancer cells and gastric cancer cells. Antigen-binding constructs in biparatopic format are internalized in HER2-expressing cells.
    Type: Application
    Filed: May 13, 2016
    Publication date: September 27, 2018
    Inventors: Eric ESCOBAR-CABRERA, Leonard G. PRESTA
  • Caninized murine antibodies to human PD-1
    Patent number: 10023636
    Abstract: The present invention provides caninized murine anti-human PD-1 antibodies that have specific sequences and a high binding affinity for canine PD-1. The invention also relates to use of these antibodies in the treatment of dogs.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: July 17, 2018
    Assignee: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey, Leonard G. Presta
  • DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS
    Publication number: 20180193477
    Abstract: Bispecific antigen-binding constructs e.g., antibodies conjugated to drugs (ADCs), which bind CD3 and other cell-surface target antigen such as tumor antigens e.g., CD19, CDH3, HER2, HER3 and EGFR antigens and methods of use are disclosed.
    Type: Application
    Filed: July 15, 2016
    Publication date: July 12, 2018
    Inventors: Gordon Yiu Kon Ng, Leonard G. Presta, Thomas Spreter Von Kreudenstein
  • ANTI-VEGF ANTIBODIES
    Publication number: 20170369564
    Abstract: Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.
    Type: Application
    Filed: January 15, 2016
    Publication date: December 28, 2017
    Applicant: Genentech, Inc.
    Inventors: Manuel Baca, James A. Wells, Leonard G. Presta, Henry B. Lowman, Yvonne Man-yee Chen
  • ANTI-GITR ANTIBODIES
    Publication number: 20170355772
    Abstract: Antibodies to human GITR are provided, as well as uses thereof, e.g., in treatment of proliferative and immune disorders.
    Type: Application
    Filed: June 16, 2017
    Publication date: December 14, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Xiao Min Schebye, Grigori P. Ermakov, Douglas J. Hodges, Leonard G. Presta